September 18th 2021
Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.
Dr. Papadimitrakopoulou on Benefits of Liquid Biopsy Versus Standard Tissue in Lung Cancer
July 16th 2019Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the benefits of liquid biopsy compared with standard tissue in lung cancer.
Genome Sequencing Studies Shake Up Views on the Cancer Mutation Landscape
July 2nd 2019Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.
Dr. Papadimitrakopoulou on Distinguishing Features of the Guardant360 Assay in Lung Cancer
June 19th 2019Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses distinguishing features of the Guardant360 assay in non–small cell lung cancer (NSCLC).
Entrectinib Breaks Through With Japanese Approval for NTRK-Positive Tumors
June 18th 2019Entrectinib received its first regulatory approval, as Japan’s Ministry of Health, Labour and Welfare has approved the drug for the treatment of adult and pediatric patients with NTRK fusion–positive, advanced recurrent solid tumors.
Expert Shares Advantages, Challenges With Liquid Biopsies in Cancer Care
May 23rd 2019Geoffrey Oxnard, MD, discusses testing error underlying liquid biopsy discordance, steps clinicians can take to optimize liquid biopsy, and where he sees this evolving in the treatment landscape for patients with cancer.
Dr. Papadimitrakopoulou on the Utility of Liquid Biopsies in NSCLC
May 11th 2019Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses the utility of liquid biopsies in non–small cell lung cancer (NSCLC).
FDA Expands Approval of PD-L1 IHC 22C3 pharmDX Assay in NSCLC
April 17th 2019The FDA has expanded the approval of the PD-L1 IHC 22C3 pharmDX assay, allowing the test to be used as a companion diagnostic to identify more patients with stage III or metastatic non–small cell lung cancer who can undergo first-line treatment with pembrolizumab (Keytruda).
Personalized Medicine Progressing in Premenopausal Breast Cancer
April 17th 2019Joyce A. O’Shaughnessy, MD, discusses the clinical implications of the TEXT and SOFT trials for women with premenopausal HR-positive, HER2-negative breast cancer, as well as unanswered questions that remain with adjuvant endocrine therapy.
Liquid Biopsies Reliably and Quickly Detect Genomic Biomarkers in Metastatic NSCLC
Vassiliki A. Papadimitrakopoulou, MD, highlights the implications of the NILE study on clinical practice and sheds light on the potential future utility of liquid biopsies in non–small cell lung cancer.
Genomic Assays Advance Personalized Care in Early-Stage Breast Cancer
April 16th 2019Mariana Chavez Mac Gregor, MD, MSc, discusses the optimal applications of these assays in patients with early-stage, HR-positive/HER2-negative breast cancer and shed light on the overall outlook of personalized medicine in this setting.